In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Defining Biopharma Dealmaking Success: An Analysis Of 2003 Alliances

Executive Summary

This article examines the question do external biopharma programs succeed at similar rates as internal projects? IN VIVO examined this question by analyzing the alliances of 2003, mining both Elsevier's Strategic Transactions database and SEC documents, and bolstering these data with independent reporting.

You may also be interested in...



US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade

HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.

Otsuka/Lundbeck Closer To Adding Alzheimer’s Agitation To Rexulti Label

With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.

Can Basilea’s Antibiotic Succeed Where Others Have Failed?

The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

IV003463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel